icometrix selected for MedTech Innovator’s 2025 Accelerator Mid-Stage Program
- Milan Walraevens
- Jun 5
- 1 min read
icometrix has been named to the prestigious 2025 MedTech Innovator Mid-Stage Accelerator cohort—an honor reserved for the top 4% of nearly 1,500 global applicants. This recognition by the industry’s leading medtech accelerator affirms what clinicians and institutions worldwide already know: icobrain is the trusted standard in AI-driven neuroimaging.
Our inclusion marks a clear validation of the breakthrough year icometrix has experienced—with icobrain aria setting a new benchmark for safety, performance, and clinical validation in AI imaging as the first FDA-cleared CADe/CADx device in neuroradiology, reimbursement now expanded to over 30 payers, growing adoption of our clinically validated solutions, and deepening collaborations with leading hospitals, pharmaceutical companies, and research institutions.
As part of the MedTech Innovator program, icometrix will:
Engage with a high-caliber network of healthcare leaders, strategic partners, and investors.
Accelerate access to the U.S. market through tailored commercialization support.
Participate in key industry events such as The MedTech Conference and MedTech Strategist Innovation Summit.
“Joining MedTech Innovator comes at a pivotal moment for icometrix, as we scale globally, secure broad payer coverage, and bring the first FDA-cleared CADe/CADx solution in neuroradiology into routine clinical use” said Wim Van Hecke, CEO of icometrix.
From enabling faster treatment decisions in multiple sclerosis to supporting early Alzheimer’s diagnosis, icobrain is already shaping the future of neurology care. Our participation in this accelerator program will further strengthen our ability to deliver secure, regulatory-cleared solutions that improve patient outcomes worldwide.
More information on the MedTech program 2025 cohort:
